-
Je něco špatně v tomto záznamu ?
Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)
C. Lebbe, C. Garbe, AJ. Stratigos, C. Harwood, K. Peris, VD. Marmol, J. Malvehy, I. Zalaudek, C. Hoeller, R. Dummer, AM. Forsea, L. Kandolf-Sekulovic, J. Olah, P. Arenberger, M. Bylaite-Bucinskiene, R. Vieira, M. Middleton, A. Levy, AM....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- Kaposiho sarkom diagnóza patologie terapie MeSH
- konsensus MeSH
- lidé MeSH
- rizikové faktory MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
Kaposi's sarcoma (KS) is a multifocal neoplasm of lymphatic endothelium-derived cells infected with human herpesvirus 8. Four clinical subtypes are distinguished: the classic, the endemic, the epidemic subtype in HIV positive patients and the iatrogenic subtype. The diagnosis is primarily based on clinical features and confirmation by histology with immunohistochemistry. Cutaneous distribution and severity, mucosal, nodal and visceral involvement depend on the type of KS with in general indolent behaviour and chronic evolution in the classic subtype and the more severe forms in iatrogenic or epidemic subtypes. Management should aim at achieving disease control. For localised lesions, several local therapies have been developed without randomised trial comparisons. Radiotherapy, intralesional chemotherapies and electrochemotherapy have high response rates. Topical treatments-imiquimod or topical 9-cis-retinoid acid-can also be used. Systemic treatments are reserved for locally aggressive extensive and disseminated KS: the recommended first-line agents are pegylated liposomal doxorubicin (PLD) and paclitaxel. In CKS, PLD or low-dose interferon-alfa are the recommended first-line agents in younger patients. In AIDS-related KS, combination antiretroviral therapy is the first treatment option; specific systemic treatment is needed only in case of extensive disease and in the prevention and treatment of immune reconstitution inflammatory syndrome. In post-transplant KS, tapering down immunosuppressive therapy and switching to mammalian target of rapamycin (m-TOR) inhibitors are used. Follow-up schedules for patients with KS disease depend on aggressiveness of the disease.
Carol Davila University of Medicine and Pharmacy Bucharest Romania
Department of Dermatology and Allergology University of Szeged Hungary
Department of Dermatology Coimbra University Hospital Centre Coimbra Portugal
Department of Dermatology Faculty of Medicine Military Medical Academy Belgrade Serbia
Department of Dermatology Hospital Clinic of Barcelona IDIBAPS and CIBER de raras Spain
Department of Dermatology Medical University of Vienna Austria
Department of Medical Oncology Gustave Roussy Comprehensive Cancer Center Villejuif Paris Sud France
University Department of Dermatology Erasme Hospital Universite´ Libre de Bruxelles Brussels Belgium
University Department of Dermatology Tuebingen Germany
University Hospital Zurich Department of Dermatology Zürich Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023893
- 003
- CZ-PrNML
- 005
- 20201214131606.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2018.12.036 $2 doi
- 035 __
- $a (PubMed)31096150
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Lebbe, Celeste $u APHP Department of Dermatology, INSERM U976, University Paris 7 Diderot, Saint-Louis University Hospital, Paris, France. Electronic address: celeste.lebbe@sls.aphp.fr.
- 245 10
- $a Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC) / $c C. Lebbe, C. Garbe, AJ. Stratigos, C. Harwood, K. Peris, VD. Marmol, J. Malvehy, I. Zalaudek, C. Hoeller, R. Dummer, AM. Forsea, L. Kandolf-Sekulovic, J. Olah, P. Arenberger, M. Bylaite-Bucinskiene, R. Vieira, M. Middleton, A. Levy, AM. Eggermont, M. Battistella, JP. Spano, JJ. Grob, C. Pages, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC),
- 520 9_
- $a Kaposi's sarcoma (KS) is a multifocal neoplasm of lymphatic endothelium-derived cells infected with human herpesvirus 8. Four clinical subtypes are distinguished: the classic, the endemic, the epidemic subtype in HIV positive patients and the iatrogenic subtype. The diagnosis is primarily based on clinical features and confirmation by histology with immunohistochemistry. Cutaneous distribution and severity, mucosal, nodal and visceral involvement depend on the type of KS with in general indolent behaviour and chronic evolution in the classic subtype and the more severe forms in iatrogenic or epidemic subtypes. Management should aim at achieving disease control. For localised lesions, several local therapies have been developed without randomised trial comparisons. Radiotherapy, intralesional chemotherapies and electrochemotherapy have high response rates. Topical treatments-imiquimod or topical 9-cis-retinoid acid-can also be used. Systemic treatments are reserved for locally aggressive extensive and disseminated KS: the recommended first-line agents are pegylated liposomal doxorubicin (PLD) and paclitaxel. In CKS, PLD or low-dose interferon-alfa are the recommended first-line agents in younger patients. In AIDS-related KS, combination antiretroviral therapy is the first treatment option; specific systemic treatment is needed only in case of extensive disease and in the prevention and treatment of immune reconstitution inflammatory syndrome. In post-transplant KS, tapering down immunosuppressive therapy and switching to mammalian target of rapamycin (m-TOR) inhibitors are used. Follow-up schedules for patients with KS disease depend on aggressiveness of the disease.
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a Kaposiho sarkom $x diagnóza $x patologie $x terapie $7 D012514
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Garbe, Claus $u University Department of Dermatology, Tuebingen, Germany.
- 700 1_
- $a Stratigos, Alexander J $u 1st Department of Dermatology- Venereology, National and Kapodistrian University of Athens, A. Sygros Hospital, Athens, Greece.
- 700 1_
- $a Harwood, Catherine $u Department of Dermatology Royal London Hospital and Centre for Cutaneous Research Blizard Institute London, United Kingdom.
- 700 1_
- $a Peris, Ketty $u Institute of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Catholic University, Rome, Italy.
- 700 1_
- $a Marmol, Veronique Del $u University Department of Dermatology, Erasme Hospital, Universite´ Libre de Bruxelles, Brussels, Belgium.
- 700 1_
- $a Malvehy, Josep $u Department of Dermatology, Hospital Clinic of Barcelona, IDIBAPS and CIBER de raras, Spain.
- 700 1_
- $a Zalaudek, Iris $u Dermatology Clinic, University of Trieste, Hospital Maggiore, Piazza dell' Ospedale 1, 34125 Trieste, Italy.
- 700 1_
- $a Hoeller, Christoph $u Department of Dermatology, Medical University of Vienna, Austria.
- 700 1_
- $a Dummer, Reinhard $u University Hospital Zurich, Department of Dermatology Zürich, Switzerland.
- 700 1_
- $a Forsea, Ana Maria $u Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- 700 1_
- $a Kandolf-Sekulovic, Lidija $u Department of Dermatology, Faculty of Medicine Military Medical Academy, Belgrade, Serbia.
- 700 1_
- $a Olah, Judith $u Department of Dermatology and Allergology University of Szeged, Hungary.
- 700 1_
- $a Arenberger, Petr $u Department of Dermatovenerology, Third Faculty of Medicine, Charles University of Prague, Prague, Czech Republic.
- 700 1_
- $a Bylaite-Bucinskiene, Matilda $u Centre of Dermatovenereology, Medical Science Institute, Medical Faculty of Vilnius University, Vilnius, Lithuania.
- 700 1_
- $a Vieira, Ricardo $u Department of Dermatology, Coimbra University Hospital Centre, Coimbra, Portugal.
- 700 1_
- $a Middleton, Mark $u Department of Oncology, Oxford National Institute for Health Research Biomedical Research Centre, United Kingdom.
- 700 1_
- $a Levy, Antonin $u Department of Radiation Oncology, Gustave Roussy, INSERM U1030, Université Paris-Saclay, F-94805, Villejuif, France.
- 700 1_
- $a Eggermont, Alexander M $u Department of Medical Oncology, Gustave Roussy Comprehensive Cancer Center, Villejuif/Paris-Sud, France.
- 700 1_
- $a Battistella, Maxime $u APHP Department of Pathology, INSERM U976, University Paris 7 Diderot, Saint-Louis University Hospital, Paris, France.
- 700 1_
- $a Spano, Jean Philippe $u Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service d'Oncologie Médicale, Paris, France.
- 700 1_
- $a Grob, Jean Jacques $u Department of Dermatology, Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
- 700 1_
- $a Pages, Cecile $u Department of Dermato-oncology, Université Paul Sabatier, Institut Universitaire du Cancer de Toulouse-Oncopole et CHU Larrey, Toulouse, France.
- 710 2_
- $a European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC)
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 114, č. - (2019), s. 117-127
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31096150 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131604 $b ABA008
- 999 __
- $a ok $b bmc $g 1596212 $s 1114569
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 114 $c - $d 117-127 $e 20190513 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20201125
